Creatine Monohydrate Use for Preventing Altitude Induced Depression
Status:
Withdrawn
Trial end date:
2019-01-07
Target enrollment:
Participant gender:
Summary
This study involves the use of an investigational drug called Creatine Monohydrate. This
means that the drug has not yet been approved by the Food & Drug Administration (FDA) for
treatment of altitude-induced depression. However, the FDA has not objected to its use to
study its safety and effectiveness for preventing altitude-induced depression. This study
will help find out what effects, good and/or bad, Creatine Monohydrate has on treating
symptoms for altitude-induced depression. Creatine Monohydrate is believed to have an effect
on improving symptoms of depression. The safety of Creatine Monohydrate in humans has been
tested in prior research studies; however, some side effects may not yet be known.